Novel viral vectors in infectious diseases

Immunology

Volumn 153, Issue 1, 2018, Pages 1-9

  Humphreys, Ian R ^a,b   Sebastian, Sarah ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

memory; T cell; vaccination; viral

Indexed keywords

ADENOVIRUS VECTOR; VIRUS VECTOR; RECOMBINANT VACCINE; VIRUS VACCINE;

ADENOVIRIDAE; ANTIGEN EXPRESSION; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; MEASLES; MEASLES VIRUS; PRIORITY JOURNAL; REVIEW; VESICULAR STOMATITIS; VESICULOVIRUS; VIRAL GENE THERAPY; VIRUS INFECTION; ADAPTIVE IMMUNITY; ANIMAL; CLASSIFICATION; COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; GENE VECTOR; GENETICS; IMMUNOLOGY; PROCEDURES; VACCINATION; VIRUS;

ADAPTIVE IMMUNITY; ANIMALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; GENETIC VECTORS; HUMANS; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRUSES;

EID: 85030464356     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12829     Document Type: Review

References (126)

1. Moss B, Smith GL, Gerin JL, Purcell RH. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 1984; 311:67–9.
2. Ertl HC. Viral vectors as vaccine carriers. Curr Opin Virol 2016; 21:1–8.
3. Dhanwani R, Ly H. Arenaviral vaccine vectors to combat infectious diseases. Oncotarget 2016; 7:44875.
4. Bonaldo MC, Sequeira PC, Galler R. The yellow fever 17D virus as a platform for new live attenuated vaccines. Hum Vaccin Immunother 2014; 10:1256–65.
5. Lundstrom K. Alphavirus-based vaccines. Viruses 2014; 6:2392–415.
6. Hu B, Tai A, Wang P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 2011; 239:45–61.
7. Volz A, Sutter G. Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 2017; 97:187–243.
8. Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol 2016; 16:367–77.
9. + T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673–85.
10. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 2008; 41:206–12.
11. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res 2011; 157:151–60.
12. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169:1984–92.
13. + T cells are polyfunctional and can respond to HCMV-infected dendritic cells in vitro. J Virol 2017; 91:e02128–16.
14. Lachmann R, Bajwa M, Vita S, Smith H, Cheek E, Akbar A et al. Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses. J Virol 2012; 86:1001–9.
15. + T cells. J Virol 2014; 88:10894–908.
16. + T cells over time. J Immunol 2003; 170:2022–9.
17. lo memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol 2000; 74:11495–503.
18. + T cell populations after murine cytomegalovirus infection. Eur J Immunol 2005; 35:1113–23.
19. + T cells, facilitating protection from local cytomegalovirus infection. Cell Rep 2015; 13:1125–36.
20. Smith CJ, Caldeira-Dantas S, Turula H, Snyder CM. Murine CMV infection induces the continuous production of mucosal resident T cells. Cell Rep 2015; 13:1137–48.
21. Gerna G, Lilleri D, Fornara C, Bruno F, Gabanti E, Cane I et al. Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host. J Gen Virol 2015; 96:360–9.
22. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293–9.
23. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523–7.
24. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001; 344:1366–71.
25. + T-cell responses driven by recombinant cytomegaloviruses. J Virol 2004; 78:2255–64.
26. Tsuda Y, Parkins CJ, Caposio P, Feldmann F, Botto S, Ball S et al. A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. Vaccine 2015; 33:2261–6.
27. Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011; 5:e1275.
28. Beverley PC, Ruzsics Z, Hey A, Hutchings C, Boos S, Bolinger B et al. A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis. J Immunol 2014; 193:2306–16.
29. Dekhtiarenko I, Jarvis MA, Ruzsics Z, Cicin-Sain L. The context of gene expression defines the immunodominance hierarchy of cytomegalovirus antigens. J Immunol 2013; 190:3399–409.
30. + T cell epitope recognition paradigms. Science 2013; 340:1237874.
31. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502:100–4.
32. + T cell responses restricted by major histocompatibility complex E. Science 2016; 351:714–20.
33. Lilja AE, Shenk T. Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proc Natl Acad Sci USA 2008; 105:19950–5.
34. Murray SE, Nesterenko PA, Vanarsdall AL, Munks MW, Smart SM, Veziroglu EM et al. Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans. J Exp Med 2017; 214:1889–99.
35. + T cell memory inflation. J Med Virol 2013; 85:1968–74.
36. + T cell memory inflation after infection with a single-cycle cytomegalovirus. PLoS Pathog 2011; 7:e1002295.
37. Mohr CA, Arapovic J, Muhlbach H, Panzer M, Weyn A, Dolken L et al. A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J Virol 2010; 84:7730–42.
38. Humphreys IR, Loewendorf A, de Trez C, Schneider K, Benedict CA, Munks MW et al. OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T cells: a CD4-dependent mechanism. J Immunol 2007; 179:2195–202.
39. + T cell memory inflation during murine cytomegalovirus infection. J Immunol 2009; 183:3932–41.
40. + T-cell inflation during cytomegalovirus latency. Eur J Immunol 2011; 41:2248–59.
41. Dekhtiarenko I, Ratts RB, Blatnik R, Lee LN, Fischer S, Borkner L et al. Peptide processing is critical for T-cell memory inflation and may be optimized to improve immune protection by CMV-based vaccine vectors. PLoS Pathog 2016; 12:e1006072.
42. + T cell memory inflation based upon a recombinant adenoviral vector. J Immunol 2013; 190:4162–74.
43. Colston JM, Bolinger B, Cottingham MG, Gilbert S, Klenerman P. Modification of antigen impacts on memory quality after adenovirus vaccination. J Immunol 2016; 196:3354–63.
44. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10:616–29.
45. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769–81.
46. + T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 2012; 109:E3503–12.
47. Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR et al. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS ONE 2011; 6:e18526.
48. + T cells induced by different adenovirus vectors. J Virol 2013; 87:1359–72.
49. Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G et al. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine 2015; 33:2944–54.
50. Ouedraogo A, Tiono AB, Kargougou D, Yaro JB, Ouedraogo E, Kabore Y et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS ONE 2013; 8:e78679.
51. Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS ONE 2012; 7:e41936.
52. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013; 207:240–7.
53. Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial. Ann Intern Med 2016; 164:313–22.
54. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 2016; 315:1610–23.
55. Shukarev G, Callendret B, Luhn K, Douoguih M, Consortium E. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. Hum Vaccin Immunother 2017; 13:266–70.
56. Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N et al. Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals. J AIDS Clin Res 2015; 6:461.
57. Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P et al. First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus-vectored HIV type 1 gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J Infect Dis 2017; 215:95–104.
58. Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O et al. A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without Interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative African adults. PLoS ONE 2015; 10:e0134287.
59. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4:115ra2.
60. Morris SJ, Sebastian S, Spencer AJ, Gilbert SC. Simian adenoviruses as vaccine vectors. Future Virol. 2016; 11:649–59.
61. A study to determine the safety and immunogenicity of a candidate MAP vaccine ChAdOx2 HAV in healthy adult volunteers. ClinicalTrials.gov/NCT03027193.
62. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T et al. A monovalent Chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med 2016; 374:1635–46.
63. Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME et al. Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med 2017; 376:928–38.
64. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2016; 16:31–42.
65. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012; 205:772–81.
66. Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA et al. Safety, immunogenicity and efficacy of prime-boost vaccination with ChAd63 and MVA encoding ME-TRAP against Plasmodium falciparum infection in adults in Senegal. PLoS ONE 2016; 11:e0167951.
67. Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nebie I et al. Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Mol Ther 2016; 24:1470–7.
68. Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S et al. A third generation vaccine for human visceral leishmaniasis and post Kala Azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis 2017; 11:e0005527.
69. Crosby CM, Barry MA. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology 2014; 462–463:158–65.
70. Crosby CM, Matchett WE, Anguiano-Zarate SS, Parks CA, Weaver EA, Pease LR et al. Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses. J Virol 2017; 91:e00720–16.
71. Crosby CM, Nehete P, Sastry KJ, Barry MA. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J Virol 2015; 89:669–75.
72. Karen KA, Deal C, Adams RJ, Nielsen C, Ward C, Espinosa DA et al. A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys. Infect Immun 2015; 83:268–75.
73. Thomas MA, Song R, Demberg T, Vargas-Inchaustegui DA, Venzon D, Robert-Guroff M. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus–host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. PLoS ONE 2013; 8:e76344.
74. Thomas MA, Nyanhete T, Tuero I, Venzon D, Robert-Guroff M. Beyond oncolytics: E1B55K-deleted adenovirus as a vaccine delivery vector. PLoS ONE 2016; 11:e0158505.
75. Berg MG, Adams RJ, Gambhira R, Siracusa MC, Scott AL, Roden RB et al. Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine. Clin Vaccine Immunol 2014; 21:1224–31.
76. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013; 13:238–50.
77. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997; 71:8531–41.
78. Fougeroux C, Holst PJ. Future prospects for the development of cost-effective adenovirus vaccines. Int J Mol Sci 2017; 18:E686.
79. Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis 1998; 27:1194–200.
80. Kuschner RA, Russell KL, Abuja M, Bauer KM, Faix DJ, Hait H et al. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine 2013; 31:2963–71.
81. Matthews QL. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 2011; 8:3–11.
82. Gu L, Li ZC, Krendelchtchikov A, Krendelchtchikova V, Wu H, Matthews QL. Using multivalent adenoviral vectors for HIV vaccination. PLoS ONE 2013; 8:e60347.
83. Tang X, Yang Y, Xia X, Zhang C, Yang X, Song Y et al. Recombinant adenoviruses displaying matrix 2 ectodomain epitopes on their fiber proteins as universal influenza vaccines. J Virol 2017; 91:e02462–16.
84. + T cells. PLoS ONE 2010; 5:e11019.
85. Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, Komarova S et al. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS ONE 2010; 5:e11815.
86. Salisch NC, Vujadinovic M, van der Helm E, Spek D, Vorthoren L, Serroyen J et al. Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform. PLoS ONE 2017; 12:e0174728.
87. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998; 72:4704–11.
88. Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090). Open Forum Infect Dis 2015; 2:ofv082.
89. Witko SE, Kotash CS, Nowak RM, Johnson JE, Boutilier LA, Melville KJ et al. An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. J Virol Methods 2006; 135:91–101.
90. Haglund K, Forman J, Krausslich HG, Rose JK. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 2000; 268:112–21.
91. Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, Draper K et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007; 360:36–49.
92. Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, Johnson JE et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008; 82:207–19.
93. Rose JK, Clarke DK. Rhabdoviruses as vaccine vectors: from initial development to clinical trials. In: Pattnaik AK, Whitt MA, eds. Biology and Pathogenesis of Rhabdo- and Filoviruses. Singapore: World Scientific, 2005:199–230.
94. Mire CE, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM, Fritz EA et al. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLoS ONE 2014; 9:e94355.
95. Evaluating the safety of and immune response to HIV-MAG DNA vaccine with or without plasmid IL-12 adjuvant delivered intramuscularly via electroporation followed by VSV-gag HIV vaccine boost in healthy, HIV-uninfected adults. ClinicalTrials.gov/NCT01578889.
96. Therapeutic vaccine for HIV. ClinicalTrials.gov/NCT01859325.
97. Evaluating the safety, tolerability, and immunogenicity of a prime-boost regimen of HIV-1 Nef/Tat/Vif, Env pDNA vaccine delivered intramuscularly with electroporation and HIV-1 rVSV envC vaccine in healthy, HIV-uninfected adults. ClinicalTrials.gov/NCT02654080.
98. Mire CE, Geisbert TW, Feldmann H, Marzi A. Ebola virus vaccines – reality or fiction? Expert Rev Vaccines 2016; 15:1421–30.
99. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 2017; 389:505–18.
100. Dahlke C, Kasonta R, Lunemann S, Krahling V, Zinser ME, Biedenkopf N et al. Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization. EBioMedicine 2017; 19:107–18.
101. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015; 15:1156–66.
102. Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 2015; 520:688–91.
103. Trial to evaluate safety and immunogenicity of an ebola zaire vaccine in healthy adults. ClinicalTrials.gov/NCT02718469.
104. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother 2017; 13:613–20.
105. International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi. ClinicalTrials.gov/NCT03072030.
106. Mire CE, Geisbert JB, Versteeg KM, Mamaeva N, Agans KN, Geisbert TW et al. A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred guinea pigs. J Infect Dis 2015; 212(Suppl 2):S384–8.
107. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399–404.
108. Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010; 16:1119–22.
109. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013; 110:1893–8.
110. Jacobson RM, Ovsyannikova IG, Vierkant RA, Pankratz VS, Poland GA. Independence of measles-specific humoral and cellular immune responses to vaccination. Hum Immunol 2012; 73:474–9.
111. Dai B, Chen ZH, Liu QC, Wu T, Guo CY, Wang XZ et al. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull World Health Organ 1991; 69:415–23.
112. + T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003; 10:411–6.
113. Howe RC, Dhiman N, Ovsyannikova IG, Poland GA. Induction of CD4 T cell proliferation and in vitro Th1-like cytokine responses to measles virus. Clin Exp Immunol 2005; 140:333–42.
114. + T cells: implications for their use as vaccines. Blood 2007; 110:1916–23.
115. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14:5773–84.
116. Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J et al. Attenuated measles virus as a vaccine vector. Vaccine 2007; 25:2974–83.
117. Naim HY. Measles virus. Hum Vaccin Immunother 2015; 11:21–6.
118. Stebbings R, Li B, Lorin C, Koutsoukos M, Fevrier M, Mee ET et al. Immunogenicity of a recombinant measles HIV-1 subtype C vaccine. Vaccine 2013; 31:6079–86.
119. Knuchel MC, Marty RR, Morin TN, Ilter O, Zuniga A, Naim HY. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector. Hum Vaccin Immunother 2013; 9:599–606.
120. Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004; 78:146–57.
121. del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 2007; 81:10597–605.
122. Clade B HIVStudy to evaluate the dosage and safety of two intramuscular injections of an investigational Vaccine. ClinicalTrials.gov/NCT01320176.
123. Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based Chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 2015; 15:519–27.
124. Phase II study to evaluate safety and immunogenicity of a Chikungunya vaccine. ClinicalTrials.gov/NCT02861586.
125. Study of a live attenuated Chikungunya vaccine in a previously epidemic area. ClinicalTrials.gov/NCT03101111.
126. Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L. Use of human monoclonal antibodies to treat Chikungunya virus infection. J Infect Dis 2013; 207:319–22.